Harbour BioMed (HKEX: 02142) announced preclinical results for LET003, a monoclonal antibody targeting ACVR2A and ACVR2B receptors developed using the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE